Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury.
Spinal Cord
; 62(8): 454-467, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38898145
Full text:
1
Database:
MEDLINE
Main subject:
Spinal Cord Injuries
/
Neuralgia
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Spinal Cord
Journal subject:
NEUROLOGIA
Year:
2024
Type:
Article
Affiliation country:
Spain